Clinical trial ZEPHIR-02
HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanced HER2-positive breast cancer (IJB-ZEPHIR02-2024)
| Organ | Breast |
|---|---|
| Trial status | Trial open for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 2 |
| Academic trial | Oui |
| Sponsor | Bordet |
| EudraCT Identifier | 2024-516253-49-00 |
| Inclusion criteria | Prior treatment with taxane, trastuzumab and pertuzumab (early or advanced setting) and T-DXd (metastatic setting). In order to be eligible, subjects must have received T-DXd as the last systemic metastatic treatment line before inclusion, and presented |
| Last update |